3-minute read
written by
Petr Kašík
tags
DIANA Biotechnologies, the Czech company that played a significant role in the fight against the coronavirus pandemic with its unique PCR tests, continues to grow, diversify its portfolio and expand into foreign markets. Petr Kašík will now be in charge of communicating the development, new technologies and future direction of the company.
Recent years have been turbulent for DIANA Biotechnologies. The fight against the Covid-19 pandemic through unique PCR tests, record growth and winning the Deloitte Fast 50 and EY Entrepreneur of the Year 2021 awards have all had specific demands on public communication, which was previously managed by TOPIC PR. Thanks to its contribution, the company has become well-known in the Czech Republic both in professional circles and among the general public.
"The scope that our company currently has is broad and very specialized. We are engaged in both basic research of new methods in several different biotechnological areas and their implementation in the form of commercial products and services. Along with this, we have decided to share the great research and development we do in the company with the professional and general public in the country and abroad through in-house PR. We would like to thank TOPIC PR for the hard years of working together during the covida pandemic," says Martin Dienstbier, CFO of DIANA Biotechnologies.
Petr Kašík will manage the communication of research, development and further direction of the company. A graduate of animal physiology at the Faculty of Physiology at Charles University with experience in the scientific and media world, co-founder of the science-popularization magazine Czechsight and the podcast Pod čepicí.
DIANA Biotechnologies has become a major player in the biotech market and is transforming into a highly diversified biotech company with global ambitions. It is expanding its portfolio mainly in clinical diagnostics and life science products and plans to focus on foreign markets in the near future. The company has also established a monoclonal antibody development division and is continuing its work on new methods for drug development. Along with this, there is a growing need to recruit the best experts and actively participate in improving the environment for cutting-edge applied research in the Czech Republic.+420734513384
All this is linked by the need to communicate highly specific topics, especially to the professional public, partners and customers in the Czech Republic and abroad. In the coming months, the company is going to launch a number of new products, especially in the field of life science. In the future, it plans to build its offer on a broad portfolio of PCR diagnostics products and unique technologies for antibody and new drug development.
Media contact:
Petr Kašík
E-mail: [email protected]
Tel: +420734513384
About DIANA Biotechnologies
DIANA Biotechnologies, a.s. is a Czech biotechnology company with strong in-house research and development. The company was founded in 2018 with the aim to develop applications of the patented DIANA technology in diagnostics and drug development. However, the company's portfolio is now significantly broader. It is currently targeting global markets in three main areas: 1) development and production of PCR products for diagnostics and life science, 2) development of proprietary original low molecular weight drugs and provision of services to the pharmaceutical sector, and 3) development of antibodies for diagnostics and therapeutics. In the field of molecular diagnostics, the company has become the largest Czech manufacturer of PCR tests for COVID-19 and other viral diseases and is now making its mark abroad thanks to its innovations in PCR diagnostics. The company is built on a team of top scientists with unique expertise in molecular biology, biochemistry, organic and medicinal chemistry, pharmacology and laboratory automation. DIANA Biotechnologies aims to become a multinational biotechnology company developing its own original diagnostics and pharmaceuticals. For more information about the company, please continue to www.dianabiotech.com